Indegene has announced the launch of a new entity in Spain.

This move marks a key step in the company’s ongoing strategic expansion in Europe and aligns with Indegene’s commitment to helping life sciences companies accelerate AI-driven innovation and make their operations future-ready.

Indegene’s new Spain entity will serve as a key delivery hub for its Europe-based clients, helping them drive hyper-personalization and significantly elevate HCP and patient experience. The company is strengthening its already existing employee base in Spain, with capabilities in medical affairs, data and analytics, creative design, engineering, digital marketing and customer experience.

“Growing R&D investments, a thriving life sciences innovation ecosystem and a high-quality talent pool make Spain a vital market and talent hub for life sciences companies in Europe. With our new entity in Spain, we can co-innovate and collaborate much better with clients, helping them use data and AI more effectively to modernize commercialization processes and fast-track business transformation,” said Manish Gupta, Chairman and CEO, Indegene.

Indegene already has a significant presence in Europe, with centers in the UK, Germany, Ireland and Switzerland. Last year, Indegene acquired Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.

In 2019, Indegene acquired DT Associates (now DT Consulting), a consulting services company in the UK that supports clients in the healthcare and life sciences space. Indegene supports many leading life sciences clients in the region in various ways across the commercialization value chain.

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products. It is one of the very few companies globally where a medical doctor and a data scientist work next to each other to solve big, impactful problems in life sciences.

More than 20 percent of Indegene’s employees come from a medical education background and they work very closely with about 600 technologists, collaborating on advanced artificial intelligence (AI), machine learning (ML) and other technologies.

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies, many emerging biotech firms, and medical device companies.

With over 5,000 employees worldwide, Indegene’s vast global footprint underscores its ability to scale and meet the evolving needs of the world’s leading pharma organizations across markets.